10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023
NA ElSayed, G Aleppo, VR Aroda, RR Bannuru… - Diabetes …, 2023 - Am Diabetes Assoc
The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …
ADA's current clinical practice recommendations and is intended to provide the components …
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular …
N Marx, M Federici, K Schütt… - European heart …, 2023 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …
off-label use of medication should be limited to situations where it is in the patient's interest …
A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
SA Harrison, P Bedossa, CD Guy… - … England Journal of …, 2024 - Mass Medical Soc
Background Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no
approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor beta …
approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor beta …
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic …
AR Lyon, T Lopez-Fernandez, LS Couch… - European Heart …, 2022 - academic.oup.com
ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …
that, unless otherwise provided for by national regulations, offlabel use of medication should …
Lipoprotein (a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement
F Kronenberg, S Mora, ESG Stroes… - European heart …, 2022 - academic.oup.com
Abstract This 2022 European Atherosclerosis Society lipoprotein (a)[Lp (a)] consensus
statement updates evidence for the role of Lp (a) in atherosclerotic cardiovascular disease …
statement updates evidence for the role of Lp (a) in atherosclerotic cardiovascular disease …
[HTML][HTML] Small interfering RNA to reduce lipoprotein (a) in cardiovascular disease
ML O'Donoghue, RS Rosenson… - … England Journal of …, 2022 - Mass Medical Soc
Background Lipoprotein (a) is a presumed risk factor for atherosclerotic cardiovascular
disease. Olpasiran is a small interfering RNA that reduces lipoprotein (a) synthesis in the …
disease. Olpasiran is a small interfering RNA that reduces lipoprotein (a) synthesis in the …
2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of …
G Mancia, R Kreutz, M Brunström, M Burnier… - Journal of …, 2023 - journals.lww.com
Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …
Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial
J Delgado-Lista, JF Alcala-Diaz, JD Torres-Peña… - The Lancet, 2022 - thelancet.com
Background Mediterranean and low-fat diets are effective in the primary prevention of
cardiovascular disease. We did a long-term randomised trial to compare the effects of these …
cardiovascular disease. We did a long-term randomised trial to compare the effects of these …
Editor's Choice–European Society for Vascular Surgery (ESVS) 2023 clinical practice guidelines on the management of atherosclerotic carotid and vertebral artery …
R Naylor, B Rantner, S Ancetti, GJ de Borst… - European Journal of …, 2023 - ejves.com
These guidelines will be updated every four years. Vascular centres are encouraged to audit
implementations made as a result of the guidelines. Audit cycles should be repeated and …
implementations made as a result of the guidelines. Audit cycles should be repeated and …
Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial
SA Harrison, R Taub, GW Neff, KJ Lucas, D Labriola… - Nature medicine, 2023 - nature.com
Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved
treatment. MAESTRO-NAFLD-1 was a 52-week randomized, double-blind, placebo …
treatment. MAESTRO-NAFLD-1 was a 52-week randomized, double-blind, placebo …